Clinical Trials
2 trialsNCT02998567 2026-05-12
HyPeR
Royal Marsden NHS Foundation Trust
Phase 1 Active not recruiting
NCT05960773 2026-05-04
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended